NCT07089173 The Effect-site Concentration of Remifentanil Blunting Endotracheal Intubation Responses During Anesthesia Induction With Lidocaine or Sufentanil Combined With Etomidate: A Randomized Controlled Study
| NCT ID | NCT07089173 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Shenzhen Hospital |
| Condition | Hemodynamics |
| Study Type | INTERVENTIONAL |
| Enrollment | 99 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2026-07-30 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The aim of this study was to compare the effect-site target concentration (including EC₅₀ and EC₉₀) of remifentanil required to suppress cardiovascular responses to tracheal intubation during anesthesia induction with etomidate combined with either lidocaine or sufentanil.
Eligibility Criteria
Inclusion Criteria: * Patients scheduled for elective surgery under general anesthesia with endotracheal intubation; * Classified as ASA physical status I-II. Exclusion Criteria: * Age \<18 years or \>65 years; * Body mass index (BMI) \>30 kg/m² or \<18.5 kg/m²; * Diagnosis of hypertension or severe cardiovascular diseases (including myocardial infarction, heart failure, atrial fibrillation, atrioventricular block, moderate-to-severe valvular diseases) or respiratory diseases (including acute exacerbation of chronic obstructive pulmonary disease, acute respiratory distress syndrome, acute asthma attack, moderate-to-severe pulmonary hypertension, severe pneumonia); * Diagnosis of obstructive sleep apnea syndrome or history of difficult intubation or preoperatively anticipated difficult airway; * Renal, hepatic or hematologic diseases; * High risk of aspiration or reflux; * Current use of analgesics for chronic pain or β-blockers for cardiovascular diseases; * Current use of psychotropic